Venclexta

(venetoclax) AbbVie

Composition:

• Available in tablet with each contains 10 mg, 50 mg or 100 mg of venetoclax

Indications:

• In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
• As monotherapy for the treatment of patients with CLL with 17p deletion who have received at least one prior therapy, or patients with CLL without 17p deletion who have received at least one prior therapy and for whom there are no other available treatment options

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.